Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance Image Source: Zacks Investment Research Amgen’s stock has been rising ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by putting their money in exchange-traded funds (ETFs) that track the performance of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

Analysts warn that these tariffs could lead to higher production costs, reduced profitability, and even drug shortages. As Trump’s tariff threats loom, investors are left questioning whether to hold ...

Amgen’s stock has been rising consistently, with corrections in between due to pipeline setbacks. Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and ...